IP Library Granted Patent US 10,501,812
Granted Patent B2
US 10,501,812 · App. 15/424,052 · Granted Dec 10, 2019

Compositions, kits and related methods for the detection and/or monitoring of

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,501,812
App. No.
15/424,052
Granted
Dec 10, 2019
Kind
B2
Abstract

Provided are compositions, kits, and methods for the identification of Listeria . In certain aspects and embodiments, the compositions, kits, and methods may provide improvements in relation to specificity, sensitivity, and speed of detection.

Claims (40)

1. A method for detecting Listeria in a sample, the method comprising:

performing a nucleic acid amplification assay using a set of oligonucleotides comprising a T7 provider oligonucleotide and a primer oligonucleotide, wherein the T7 provider oligonucleotide and the primer oligonucleotide target sequences in a region of Listeria nucleic acid corresponding to nucleotides 1180-1370 of the 16S rRNA of E. coli , represented by SEQ ID NO:113, and wherein the T7 provider oligonucleotide and the primer oligonucleotide used in said amplification assay target opposite strands of the Listeria nucleic acid sequence to be amplified, and

detecting the presence or absence of amplification product, wherein the presence of the amplification product indicates the presence of Listeria in the sample.

2. The method of claim 1 , wherein the detecting step utilizes a detection oligonucleotide that specifically hybridizes to the amplification product.

3. The method of claim 2 , wherein the detection oligonucleotide is a molecular torch.

4. The method of claim 3 , wherein

the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:55,

the primer oligonucleotide has a sequence consisting of SEQ ID NO:65, and

the molecular torch has a sequence consisting of SEQ ID NO:72, SEQ ID NO:77, SEQ ID NO:78, or SEQ ID NO:79.

5. The method of claim 4 , wherein the molecular torch has the sequence consisting of SEQ ID NO:72.

6. The method of claim 4 , wherein the molecular torch has the sequence consisting of SEQ ID NO:77.

7. The method of claim 4 , wherein the molecular torch has the sequence consisting of SEQ ID NO:78.

8. The method of claim 4 , wherein the molecular torch has the sequence consisting of SEQ ID NO:79.

9. The method of claim 3 , wherein

the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:55,

the primer oligonucleotide has a sequence consisting of SEQ ID NO:64, SEQ ID NO:65, or SEQ ID NO:68, and

the molecular torch has a sequence consisting of SEQ ID NO:78.

10. The method of claim 9 , wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:64.

11. The method of claim 9 , wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:68.

12. The method of claim 3 , wherein

the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:57,

the primer oligonucleotide has a sequence consisting of SEQ ID NO:64 or SEQ ID NO:65, and

the molecular torch has a sequence consisting of SEQ ID NO:78.

13. The method of claim 12 , wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:64.

14. The method of claim 12 , wherein the primer oligonucleotide has the sequence consisting of SEQ ID NO:65.

15. The method of claim 3 , wherein

the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:57,

the primer oligonucleotide has a sequence consisting of SEQ ID NO:64, and

the molecular torch has a sequence consisting of SEQ ID NO:72 or SEQ ID NO:78.

16. The method of claim 15 , wherein the molecular torch oligonucleotide has the sequence consisting of SEQ ID NO:72.

17. The method of claim 3 , wherein

the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:55, or SEQ ID NO:57,

the primer oligonucleotide has a sequence consisting of SEQ ID NO:64, and

the molecular torch has a sequence consisting of SEQ ID NO:78.

18. The method of claim 17 , wherein the T7 provider oligonucleotide has the sequence consisting of SEQ ID NO:49.

19. The method of claim 17 , wherein the T7 provider oligonucleotide has the sequence consisting of SEQ ID NO:50.

20. The method of claim 3 , wherein

the T7 provider oligonucleotide has a sequence consisting of SEQ ID NO:47,

the primer oligonucleotide has a sequence consisting of SEQ ID NO:68, and

the molecular torch has a sequence consisting of SEQ ID NO:79.

Assignments (4)
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY INTEREST Recorded Oct 15, 2020
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; FOCAL THERAPEUTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 054089/0804 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 26, 2020
From: RESHATOFF, MICHAEL R.; LIVEZEY, KRISTIN W.; HOGAN, JAMES J.
To: GEN-PROBE INCORPORATED
Reel/Frame 053059/0493 →
SECURITY INTEREST Recorded Apr 19, 2017
From: HOLOGIC, INC.; GEN-PROBE INCORPORATED; SUROS SURGICAL SYSTEMS, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 042055/0241 →